News Biosimilars unlock use of bevacizumab in bowel cancer by NHS More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time.
Digital Six ways the NHS can become the UK’s greatest testbed for te... There are six priorities that would turn the NHS into the UK’s flagship testbed for innovation.
Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
Patients The NHS, system burden, and a transformation prescription, w... Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, discusses her book on the NHS.
News UK confirms lower clawback rate for NHS medicines The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step."
News NHS use of digital cardiac rehab tools endorsed Seven digital health technologies used to support people recovering from cardiovascular diseases have been recommended for use by the NHS.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.